Anaes Vivas · Neuromuscular blockade & reversal
Neuromuscular blockade & reversal — Viva
Clinical viva on reversal mechanisms, depth-based dosing, quantitative monitoring and residual blockade
On this page
Study tools
Target exams
ANZCAFRCAABAEDAICFCAIFCA_SA
Prompt
Neuromuscular blockade & reversal
Viva Stems
- Why is the head-lift test inadequate, and what threshold replaces it?
- Contrast neostigmine and sugammadex mechanisms and depth limits.
- State the three depth-based sugammadex doses.
- Did faster reversal translate into better outcomes in SNaPP?
References4ShowHide
- [2]Hristovska AM, et al. Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults. Cochrane Database of Systematic Reviews, 2017.PMID 28806470
- [5]Naguib M, et al. Consensus Statement on Perioperative Use of Neuromuscular Monitoring. Anesthesia and Analgesia, 2018.PMID 29200077
- [6]Leslie K, et al. Sugammadex versus neostigmine for reversal of neuromuscular blockade and postoperative pulmonary complications (SNaPP): an international, randomised, controlled, phase 4 trial. Lancet Respir Med, 2026.PMID 42263720
- [10]Lee C, et al. Reversal of profound neuromuscular block by sugammadex administered three minutes after rocuronium: a comparison with spontaneous recovery from succinylcholine. Anesthesiology, 2009.PMID 19387176